WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002007777) USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/007777    International Application No.:    PCT/US2001/041412
Publication Date: 31.01.2002 International Filing Date: 26.07.2001
Chapter 2 Demand Filed:    25.02.2002    
IPC:
A61K 38/17 (2006.01), A61K 38/21 (2006.01), A61K 48/00 (2006.01)
Applicants: SCHERING AKTIENGESELLSCHAFT [DE/DE]; 13342 Berlin (DE) (For All Designated States Except US).
CROZE, Ed [US/US]; (US) (For US Only).
VOGEL, David [US/US]; (US) (For US Only).
RUSSEL-HARDE, Dean [US/US]; (US) (For US Only)
Inventors: CROZE, Ed; (US).
VOGEL, David; (US).
RUSSEL-HARDE, Dean; (US)
Agent: ZELANO, Anthony, J.; Millen, White, Zelano & Branigan, P.C., Suite 1400, Arlington Courthouse Plaza I, 2200 Clarendon Boulevard, Arlington, VA 22201 (US)
Priority Data:
60/220,844 26.07.2000 US
09/912,252 25.07.2001 US
Title (EN) USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS
(FR) UTILISATION DE LA CHAINE POLYPEPTIDE DU RECEPTEUR 2C D'INTERFERON POUR RENFORCER LES EFFETS ANTI-CROISSANCE DES INTERFERONS DE TYPE I
Abstract: front page image
(EN)The present invention is directed towards a method of potentiating the anti-growth effects of type I interferon (IFN) on cells in a target cell population comprising increasing the number of functional IFNAR2c receptors on the surface of modified cells within the target cell population and then exposing the modified cells to a therapeutically effective amount of a type I IFN or by exposure to endogenously produced IFN.
(FR)L'invention concerne un procédé destiné à potentialiser les effets anti-croissance de l'interféron de type I (IFN) sur des cellules dans une population cellulaire, qui consiste à augmenter le nombre de récepteurs IFNAR2c sur la surface des cellules modifiées à l'intérieur de la population cellulaire cible et à exposer les cellules modifiées à une dose thérapeutiquement efficace de l'IFN de type I ou à l'IFN produit de manière endogène.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)